

PROFESSIONAL INFORMATION

SCHEDULING STATUS:

S4

1. NAME OF THE MEDICINAL PRODUCT:

AGGREVA 0,05 mg/ml (Solution for Infusion)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION:

Each 1 ml solution of AGGREVA 0,05 mg/ml solution for infusion contains 0,05 mg/ml tirofiban base.

AGGREVA 0,05 mg/ml is sugar free.

For full list of excipients, see **section 6.1**.

3. PHARMACEUTICAL FORM

Solution for infusion. Clear, colourless solution, free from visible particles.

pH 5,5 to 6,5.

4. CLINICAL PARTICULARS:

4.1 Therapeutic indications:

AGGREVA 0,05 mg/ml, in combination with heparin, is indicated for patients with unstable angina or non-Q-wave myocardial infarction, presenting with ECG abnormalities or elevated cardiac enzymes, to prevent cardiac ischaemic events and is also indicated for patients with coronary ischaemic syndromes undergoing coronary angioplasty or atherectomy to prevent cardiac ischaemic complications related to abrupt closure of the treated coronary artery (see **section 4.2**).

4.2 Posology and method of administration:

Posology:

AGGREVA 0,05 mg/ml is recommended for use with calibrated infusion device. Care should be taken to avoid a prolonged loading infusion. Care should also be taken in calculating the bolus dose and infusion rates based on patient weight.

In clinical studies patients received aspirin, unless contraindicated.

Unstable Angina Pectoris or Non-Q-Wave Myocardial Infarction:

In patients who are to be managed medically for unstable angina/non-Q-wave myocardial infarction and who may continue on to angioplasty or atherectomy, AGGREVA 0,05 mg/ml should be administered intravenously, in combination with heparin, at the initial infusion rate of 0,4 microgram/kg/min for 30 minutes. Upon completion of the initial infusion, AGGREVA 0,05 mg/ml should be continued at a maintenance infusion rate of 0,1 microgram/kg/min. Patients with severe renal insufficiency (creatinine clearance less than 30 ml/min) should receive half the usual rate of infusion.

The table below is provided as a guide to dosage adjustment by weight.

	Most Patients		Severe Renal Impairment	
Patient weight (kg)	30 Min Loading Infusion Rate (ml/hr)	Maintenance Infusion Rate (ml/hr)	30 Min Loading Infusion Rate (ml/hr)	Maintenance Infusion Rate (ml/hr)
30 to 37	16	4	8	2
38 to 45	20	5	10	3
46 to 54	24	6	12	3
55 to 62	28	7	14	4
63 to 70	32	8	16	4
71 to 79	36	9	18	5
80 to 87	40	10	20	5
88 to 95	44	11	22	6
96 to 104	48	12	24	6
105 to 112	52	13	26	7
113 to 120	56	14	28	7
121 to 128	60	15	30	8
129 to 137	64	16	32	8
138 to 145	68	17	34	9
146 to 153	72	18	36	9

AGGREVA 0,05 mg/ml in combination with heparin has been administered for 48 to 108 hours, on average patients received AGGREVA 0,05 mg/ml for 71,3 hours. This infusion can be continued through angiography and should be continued up to 12 to 24 hours post-angioplasty/atherectomy. Arterial sheaths should be removed when the patient's activated clotting time is less than 180 seconds or 2 to 6 hours following cessation of heparin.

Angioplasty/Atherectomy:

In patients in whom AGGREVA 0,05 mg/ml is initiated in the setting of angioplasty/atherectomy, AGGREVA 0,05 mg/ml should be administered intravenously, in combination with heparin, as an initial bolus of 10 microgram/kg administered over 3 minutes followed by a maintenance infusion rate of 0,15 microgram/kg/min.

Renal insufficiency:

Patients with severe renal insufficiency (creatinine clearance less than 30 ml/min) should receive half the usual dosage. The table below is provided as a guide to dosage adjustment by weight.

	Most Patients		Severe Renal Impairment	
Patient weight (kg)	Bolus to be administered over 3 minutes (ml)	Maintenance Infusion Rate (ml/hr)	Bolus to be administered over 3 minutes (ml)	Maintenance Infusion Rate (ml/hr)
30 to 37	7	6	4	3
38 to 45	8	8	4	4
46 to 54	10	9	5	5
55 to 62	12	11	6	6
63 to 70	13	12	7	6
71 to 79	15	14	8	7
80 to 87	17	15	9	8
88 to 95	18	17	9	9
96 to 104	20	18	10	9
105 to 112	22	20	11	10
113 to 120	23	21	12	11

121 to 128	25	23	13	12
129 to 137	26	24	13	12
138 to 145	28	26	14	13
146 to 153	30	27	15	14

The AGGREVA 0,05 mg/ml maintenance infusion should be administered for 36 hours. Upon completion of the procedure, heparin should be discontinued, and arterial sheaths should then be removed when the patient's activated clotting time is less than 180 seconds.

Other Patient Populations:

No dosage adjustment is recommended for elderly patients (see **section 4.4** Use in the Elderly) or female patients.

Paediatric population:

The safety and efficacy of AGGREVA in children have not been established.

Method of administration:

AGGREVA 0,05 mg/ml is for intravenous use only using sterile equipment. AGGREVA 0,05 mg/ml may be co-administered with heparin through the same line.

Directions for use:

Parenteral medicines should be inspected visually for particulate matter and discolouration prior to use, whenever solution and container permit.

AGGREVA 0,05 mg/ml may be administered in the same intravenous line as atropine sulphate, dobutamine, dopamine, epinephrine HCl (adrenaline), furosemide, lidocaine, midazolam HCl, morphine sulphate, nitroglycerin, potassium chloride, propranolol HCl and famotidine injection.

AGGREVA 0,05 mg/ml should not be administered in the same intravenous line as diazepam (see **section 6.2**).

Check the expiry date.


Do not withdraw solution directly from the container with a syringe.

To open: Tear foil over pouch (250 ml Solution for Infusion) at notch and remove inner container. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as sterility may be impaired. Do not use unless solution is clear and seal is intact.


Do not add supplementary medication or withdraw solution directly from the bag with a syringe.

CAUTION: Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before administration of the fluid from the secondary container is completed.

Preparation for administration:



1. Identify the administration infusion port.



2. Remove the vial stopper cover from the administration infusion port.

3. Insert infusion set needle into the administration infusion port.
4. Hang the bag on the infusion stand. Press drip chamber to get fluid level. Prime infusion set. Connect

and adjust flow rate.

Use according to the dosage table above. Check for minute leaks by squeezing inner bag firmly.

Preparation for administration:

1. Suspend container from eyelet support.
2. Remove plastic protector from outlet port at bottom of container.
3. Attach administration set. Refer to complete directions accompanying set.
4. Any unused intravenous solution should be discarded.

4.3 Contraindications:

- Hypersensitivity to tirofiban or to any of the excipients listed in **section 6.1**.
- Active internal bleeding or history of bleeding diathesis within the previous 30 days.
- A history of intracranial haemorrhage, intracranial neoplasm, arteriovenous malformation or aneurysm.
- A history of thrombocytopenia following prior exposure to AGGREVA 0,05 mg/ml.
- Major surgical procedure or severe physical trauma within the previous month.
- History of stroke within 30 days or any history of haemorrhagic stroke.
- History, symptoms, or findings suggestive of aortic dissection.
- Severe hypertension (systolic blood pressure more than 180 mmHg and/or diastolic blood pressure more than 110 mmHg).
- Acute pericarditis.
- Concomitant use of another parenteral GP IIb/IIIa.
- Recent epidural procedure.
- Chronic haemodialysis.
- Prolonged INR.

Paediatric use:

Safety and effectiveness in children have not been established.

4.4 Special warnings and precautions for use:

The administration of AGGREVA 0,05 mg/ml alone without unfractionated heparin is not recommended.

There is limited experience with concomitant administration of AGGREVA 0,05 mg/ml with enoxaparin (see **section 5.2**). The concomitant administration of AGGREVA 0,05 mg/ml with enoxaparin is associated with a higher frequency of cutaneous and oral bleeding events, but not in TIMI bleeds**, when compared with the concomitant administration of AGGREVA 0,05 mg/ml and unfractionated heparin. An increased risk of serious bleeding events associated with the concomitant administration of AGGREVA 0,05 mg/ml and enoxaparin cannot be excluded, particularly in patients given additional unfractionated heparin in conjunction with angiography and/or PCI. The efficacy of AGGREVA 0,05 mg/ml in combination with enoxaparin has not been established. The safety and efficacy of AGGREVA 0,05 mg/ml with other low molecular weight heparins has not been investigated.

There is insufficient experience with the use of AGGREVA 0,05 mg/ml in the following diseases and conditions, however, an increased risk of bleeding is suspected. Therefore, AGGREVA 0,05 mg/ml is not recommended in:

- Traumatic or protracted cardiopulmonary resuscitation, organ biopsy or lithotripsy within the past two weeks.
- Severe trauma or major surgery > 6 weeks but < 3 months previously.
- Active peptic ulcer within the past three months.
- Uncontrolled hypertension (> 180/110 mm Hg).
- Acute pericarditis.
- Active or a known history of vasculitis.
- Suspected aortic dissection.
- Haemorrhagic retinopathy.
- Occult blood in the stool or haematuria.
- Thrombolytic therapy (see **section 4.5**).
- Concurrent use of medicines that increase the risk of bleeding to a relevant degree (see **section 4.5**).

There is no therapeutic experience with AGGREVA 0,05 mg/ml in patients for whom thrombolytic therapy is indicated. Consequently, the use of AGGREVA 0,05 mg/ml is not recommended in combination with thrombolytic therapy.

AGGREVA 0,05 mg/ml infusion should be stopped immediately if circumstances arise that necessitate thrombolytic therapy (including acute occlusion during PCI) or if the patient must undergo an emergency coronary artery bypass graft (CABG) operation or requires an intra-aortic balloon pump.

Paediatric population:

There is no therapeutic experience with AGGREVA 0,05 mg/ml in children, thus, the use of AGGREVA 0,05 mg/ml is not recommended in these patients.

Other precautionary notes and measures:

There are insufficient data regarding the re-administration of AGGREVA 0,05 mg/ml.

Patients should be carefully monitored for bleeding during treatment with AGGREVA 0,05 mg/ml. If treatment of haemorrhage is necessary, discontinuation of AGGREVA 0,05 mg/ml should be considered (see **section 4.9**). In cases of major or uncontrollable bleeding, tirofiban hydrochloride should be discontinued immediately.

AGGREVA 0,05 mg/ml should be used with special caution in the following conditions and patient groups:

- Recent clinically relevant bleeding (less than one year).
- Puncture of a non-compressible vessel within 24 hours before administration of AGGREVA 0,05 mg/ml.
- Recent epidural procedure (including lumbar puncture and spinal anaesthesia).
- Severe acute or chronic heart failure.
- Cardiogenic shock.
- Mild to moderate liver insufficiency.
- Platelet count < 150 000/mm³, known history of coagulopathy or platelet function disturbance or thrombocytopenia.
- Haemoglobin concentration less than 11 g/dl or haematocrit < 34 %.

Special caution should be used during concurrent administration of ticlopidine, clopidogrel, adenosine, dipyridamole, sulfinpyrazone, and prostacyclin.

Elderly patients, female patients, and patients with low body weight:

Elderly and/or female patients had a higher incidence of bleeding complications than younger or male patients, respectively. Patients with a low body weight had a higher incidence of bleeding than patients with a higher body weight. For these reasons AGGREVA 0,05 mg/ml should be used with caution in these patients and the heparin effect should be carefully monitored.

Impaired renal function:

There is evidence from clinical studies that the risk of bleeding increases with decreasing creatinine clearance and hence also reduced plasma clearance of tirofiban. Patients with decreased renal function (creatinine clearance <60ml/min) should therefore be carefully monitored for bleeding during treatment with AGGREVA 0,05 mg/ml and the heparin effect should be carefully monitored. In severe kidney failure the AGGREVA 0,05 mg/ml dosage should be reduced (see **section 4.2**).

Femoral artery line:

During treatment with AGGREVA 0,05 mg/ml there is a significant increase in bleeding rates, especially in the femoral artery area, where the catheter sheath is introduced. Care should be taken to ensure that only the anterior wall of the femoral artery is punctured. Arterial sheaths may be removed when coagulation has returned to normal, e.g., when activated clotting time (ACT) is less than 180 seconds, (usually 2 to 6 hours after discontinuation of heparin).

After removal of the introducer sheath, careful haemostasis should be ensured under close observation.

General nursing care:

The number of vascular punctures, and intramuscular injections should be minimised during the treatment with AGGREVA 0,05 mg/ml. I.V. access should only be obtained at compressible sites of the body. All vascular puncture sites should be documented and closely monitored. The use of urinary catheters, nasotracheal intubation and nasogastric tubes should be critically considered.

Monitoring of laboratory values:

Platelet count, haemoglobin and haematocrit levels should be determined before treatment with AGGREVA 0,05 mg/ml as well as within 2 to 6 hours after start of therapy with AGGREVA 0,05 mg/ml and at least once daily thereafter while on therapy (or more often if there is evidence of a marked decrease). In patients who have previously received GPIIb/IIIa receptor antagonists (cross reactivity can occur), the platelet count should be monitored immediately e.g., within the first hour of administration after re-exposure (see **section 4.8**). If the platelet count falls below 90 000/mm³, further platelet counts should be carried out in order to rule out pseudo-thrombocytopenia. If thrombocytopenia is confirmed, AGGREVA 0,05 mg/ml and heparin should be discontinued. Patients should be monitored for bleeding and treated if necessary (see **section 4.9**).

In addition, activated thromboplastin time (APTT) should be determined before treatment and the anticoagulant effects of heparin should be carefully monitored by repeated determinations of APTT and the dose should be adjusted accordingly (see **section 4.2**). Potentially life-threatening bleeding may occur especially when heparin is administered with other products affecting haemostasis, such as GPIIb/IIIa receptor antagonists.

Sodium content:

AGGREVA 0,05 mg/ml solution for infusion contains approximately 2 412,50 mg of sodium per 250 ml bag which should be taken into consideration by patients on a controlled sodium diet.

**TIMI major bleeds are defined as a haemoglobin drop of > 50g/l with or without an identified site, intracranial haemorrhage, or cardiac tamponade. TIMI minor bleeds are defined as a haemoglobin drop of > 30 g/l but ≤ 50 g/l with bleeding from a known site or spontaneous gross haematuria, haematemesis, or haemoptysis. TIMI “loss no site” is defined as a haemoglobin drop > 40 g/l but < 50 g/l without an identified bleeding site.

4.5 Interaction with other medicines and other forms of interaction:

The use of several platelet aggregation inhibitors increases the risk of bleeding, likewise their combination

with heparin, warfarin and thrombolytics. Clinical and biological parameters of haemostasis should be regularly monitored.

The concomitant administration of AGGREVA 0,05 mg/ml and aspirin increases the inhibition of platelet aggregation to a greater extent than aspirin alone, as measured by ex vivo APD- induced platelet aggregation test. The concomitant administration of AGGREVA 0,05 mg/ml and unfractionated heparin increases the prolongation of the bleeding time to a greater extent as compared to unfractionated heparin alone.

With the concurrent use of AGGREVA 0,05 mg/ml, unfractionated heparin, aspirin, and clopidogrel there was a comparable incidence of bleeding than when only unfractionated heparin, aspirin, and clopidogrel were used together (see **sections 4.4** and **4.8**).

AGGREVA 0,05 mg/ml prolonged bleeding time; however, the combined administration of AGGREVA 0,05 mg/ml and ticlopidine did not additionally affect bleeding time.

Concomitant use of warfarin with AGGREVA 0,05 mg/ml plus heparin was associated with an increased risk of bleeding.

AGGREVA 0,05 mg/ml is not recommended in thrombolytic therapy - concurrent or less than 48 hours before administration of AGGREVA 0,05 mg/ml or concurrent use of medicines that increase the risk of bleeding to a relevant degree (e.g., oral anticoagulants, other parenteral GP IIb/IIIa inhibitors, dextran solutions). There is insufficient experience with the use of AGGREVA 0,05 mg/ml in these conditions; however, an increased risk of bleeding is suspected.

Tirofiban has been used concomitantly in clinical studies with beta-blockers, calcium channel blockers, NSAIDs and nitrate preparations without evidence of clinically significant adverse interactions.

Effects of other medicines:

The plasma clearance of tirofiban in patients receiving one of the following medicines was compared to that in patients not receiving that medicine in a sub-set of patients in the PRISM study. There were no

substantial (>15 %) effects of these medicines on the plasma clearance of tirofiban: acebutolol, alprazolam, amlodipine, aspirin preparations, atenolol, bromazepam, captopril, diazepam, digoxin, diltiazem, docusate sodium, enalapril, furosemide, glibenclamide, unfractionated heparin, insulin, isosorbide, lorazepam, lovastatin, metoclopramide, metoprolol, morphine, nifedipine, nitrate preparations, oxazepam, paracetamol, potassium chloride, propranolol, ranitidine, simvastatin, sucralfate and temazepam.

The pharmacokinetics and pharmacodynamics of AGGREVA 0,05 mg/ml were investigated when concomitantly administered with enoxaparin (1 milligram/kg subcutaneously every 12 hours) and compared with the combination of AGGREVA 0,05 mg/ml and unfractionated heparin. There was no difference in the clearance of AGGREVA 0,05 mg/ml between the two groups.

4.6 Fertility, pregnancy and lactation:

Safety and efficacy in pregnancy and lactation has not been established.

Pregnancy:

There are no or limited amount of data from the use of tirofiban hydrochloride in pregnant women. Animal studies are insufficient with respect to reproductive toxicity (see **section 5.3**). AGGREVA 0,05 mg/ml should not be used during pregnancy.

Breastfeeding:

It is unknown whether tirofiban hydrochloride is excreted in human milk. Available pharmacodynamic/toxicological data in animals have shown excretion of tirofiban hydrochloride in milk (for details see **section 5.3**). A risk to the new-born cannot be excluded.

AGGREVA 0,05 mg/ml should not be used during lactation.

Fertility:

Animal studies are insufficient to draw conclusions with respect to reproductive toxicity in humans.

4.7 Effects on ability to drive and use machines:

Not relevant.

4.8 Undesirable effects:

a. Summary of safety profile:

The most common adverse reaction reported during therapy with AGGREVA 0,05 mg/ml, when used concomitantly with heparin, aspirin and other oral anti-platelet medicines, was bleeding, which usually involved mild mucocutaneous bleeding or mild catheterisation-site bleeding.

Gastro-intestinal, retro-peritoneal, intracranial, haemorrhoidal and post-operative bleeding, epidural haematoma in the spinal region, haemopericardium and pulmonary (alveolar) haemorrhage have also been reported. The most serious adverse reaction was fatal bleeding.

b. Tabulated list of adverse reactions:

System Organ Class	Frequent	Less frequent	Frequency unknown
Blood and lymphatic system disorders			Acute and/or severe (< 20 000/mm ³) decreases in platelet counts. Intracranial bleeding, spinal epidural haematoma
Immune system disorders			Severe allergic reactions including anaphylactic reactions.
Nervous system disorders	Headache		
Cardiac disorders			Haemopericardium
Vascular disorders	Haematoma		
Respiratory, thoracic and mediastinal disorders	Haemoptysis, epistaxis		Pulmonary (alveolar) haemorrhage

Gastrointestinal disorders	Nausea, oral haemorrhage, gingival haemorrhage	GI haemorrhage, haematemesis	Retroperitoneal bleeding
Skin and subcutaneous tissue disorders	Ecchymosis		
Renal and urinary disorders	Haematuria		
General disorders and administration site conditions	Fever		
Injury, poisoning and procedural complications	Post-operative haemorrhage*, vessel puncture site haemorrhage		
Investigations	Occult blood in stool or urine, decreases in haematocrit and haemoglobin, platelet counts < 90 000/mm ³	Platelet counts < 50 000/mm ³	

*Primarily related to catheterisation sites.

c. Description of selected adverse reactions:

Bleeding:

Both, with the AGGREVA 0,05 mg/ml 0,4 microgram/kg/min infusion regimen and the 25 microgram/kg dose bolus regimen, rates of major bleeding complications are low and not significantly increased.

Thrombocytopenia:

During AGGREVA 0,05 mg/ml therapy, acute decreases in platelet count or thrombocytopenia occurred

more frequently than in the placebo group. These decreases were reversible upon discontinuation of AGGREVA 0,05 mg/ml. Acute and severe platelet (platelet counts < 20 000/mm³) decreases have been observed in patients with no prior history of thrombocytopenia upon re-administration of GPIIb/IIIa receptor antagonists and may be associated with chills, low-grade fever or bleeding complications.

Allergic reactions:

Severe allergic reactions (e.g., bronchospasm, urticaria) including anaphylactic reactions have occurred during initial treatment (also on the first day) and during re-administration of AGGREVA 0,05 mg/ml. Some cases have been associated with severe thrombocytopenia (platelet counts < 10 000/mm³).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare providers are asked to report any suspected adverse reactions to SAHPRA via the **6.04 Adverse Drug Reactions Reporting Form**, found online under SAHPRA's publications: <https://www.sahpra.org.za/Publications/Index/8>.

4.9 Overdose:

Inadvertent overdose with tirofiban hydrochloride occurred in the clinical studies, up to 50 microgram/kg as a three-minute bolus or 1,2 microgram/kg/min as an initial infusion. Overdose with up to 1,47 microgram/kg/min as a maintenance infusion rate has also occurred.

a) Symptoms of overdose:

The symptom of overdose most commonly reported was bleeding, usually mucosal bleeding and localised bleeding at the arterial puncture site for cardiac catheterisation but also single cases of intracranial haemorrhages and retroperitoneal bleedings (see **sections 4.4** and **5.1**).

b) Measures:

Overdose with AGGREVA 0,05 mg/ml should be treated in accordance with the patient's condition and the attending medical practitioner's assessment. If treatment of haemorrhage is necessary, the AGGREVA 0,05 mg/ml infusion should be discontinued. Transfusions of blood and/or thrombocytes should also be

considered. AGGREVA 0,05 mg/ml can be removed by haemodialysis.

5. PHARMACOLOGICAL PROPERTIES:

5.1 Pharmacodynamic properties:

A 8.2 Medicines acting on blood and haemopoietic system; Anticoagulants

Pharmacotherapeutic group: Blood and blood forming organs – antithrombotic agents Platelet aggregation inhibitors excluding heparin.

ATC-Code: B01A C17

Mechanism of action:

Tirofiban is a non-peptide antagonist of the GP IIb/IIIa receptor, the major platelet surface receptor involved in platelet aggregation. Tirofiban prevents binding of fibrinogen to GP IIb/IIIa, thereby blocking the cross-linking of platelets and platelet aggregation.

Tirofiban causes inhibition of platelet function as demonstrated by its ability to inhibit ex vivo adenosine phosphate (ADP)-induced platelet aggregation and prolong bleeding time (BT) in healthy subjects and patients with coronary artery disease. The time course of inhibition parallels the plasma concentration profile of the medicine. Following discontinuation of an infusion of tirofiban, platelet function rapidly returns to baseline.

In patients with unstable angina, a two-staged intravenous infusion regimen of AGGREVA 0,05 mg/ml (loading infusion of 0,4 microgram/kg/min for 30 minutes followed by 0,1 microgram/kg/min for up to 48 hours in the presence of heparin and aspirin), produces approximately 90 % inhibition of ex vivo ADP-induced platelet aggregation with a 2,9-fold prolongation of bleeding time during the infusion.

Inhibition was achieved rapidly with the 30-minute loading infusion and was maintained over the duration of the infusion.

In patients in whom AGGREVA 0,05 mg/ml is initiated in the setting of coronary angioplasty, a two-staged intravenous infusion regimen of AGGREVA 0,05 mg/ml (loading bolus of 10 microgram/kg over 5 minutes

followed by a maintenance infusion of 0,15 microgram/kg/min for 16 to 24 hours), administered in combination with heparin and aspirin, produces approximately more than 90 % inhibition of ex vivo ADP-induced platelet aggregation in nearly all patients. Near maximal inhibition is achieved rapidly with the 5 minute bolus and is maintained over the duration of the infusion. Following discontinuation of the infusion of AGGREVA 0,05 mg/ml, platelet function rapidly returns to near baseline in approximately 90 % of patients with coronary artery disease in 4 to 8 hours.

5.2 Pharmacokinetic properties:

Distribution:

Tirofiban is not highly bound to plasma proteins and protein binding is concentration independent over the range of 0,01 to 25 microgram/ml. Unbound fraction in human plasma is 35 %. The steady state volume of distribution of tirofiban ranges from 22 to 42 litres. Tirofiban crosses the placenta in rats and rabbits.

Biotransformation:

Profiling of ¹⁴C-labelled tirofiban in urine and faeces indicates that the radioactivity was accounted for mainly by unchanged tirofiban. Circulating plasma radioactivity is accounted for mainly by unchanged tirofiban (up to 10 hours post dose). These data suggest limited metabolism of tirofiban.

Elimination:

Following an intravenous dose of ¹⁴C-labelled tirofiban in healthy subjects, 66 % of radioactivity is recovered in the urine and 23 % in the faeces. Total radioactivity recovery is about 91 %. Both urinary and biliary excretion contribute significantly to the elimination of tirofiban.

In healthy subjects, the plasma clearance of tirofiban ranges from 213 to 314 ml/min. Renal clearance accounts for 39 to 69 % of plasma clearance. Half-life ranges from 1,4 to 1,8 hours.

In patients with coronary artery disease, the plasma clearance of tirofiban ranges from 152 to 267 ml/min. Renal clearance accounts for 39 % of plasma clearance. Half-life ranges from 1,9 to 2,2 hours.

Significant levels of tirofiban are excreted in rat milk. Excretion into milk has not been studied in humans.

Special populations:***Gender:***

The plasma clearance of tirofiban in patients with coronary heart disease is similar in men and women.

Elderly patients:

The plasma clearance of tirofiban is about 25 % less in elderly (> 65 years) patients with coronary heart disease in comparison to younger ($\leq$ 65 years) patients.

Ethnic groups:

No difference was found in the plasma clearance between patients of different ethnic groups.

Coronary Artery Disease:

In patients with unstable angina pectoris or NQWMI the plasma clearance was about 200 ml/min, the renal clearance 39 % of the plasma clearance. The half-life is about two hours.

Renal impairment:

In clinical studies, patients with decreased renal function showed a reduced plasma clearance of tirofiban depending on the degree of impairment of creatinine clearance. In patients with a creatinine clearance of less than 30 ml/min, including haemodialysis patients, the plasma clearance of tirofiban is reduced to a clinically relevant extent (over 50 %) (see **section 4.2**). Tirofiban is removed by haemodialysis.

Liver failure:

There is no evidence of a clinically significant reduction of the plasma clearance of tirofiban in patients with mild to moderate liver failure. No data are available on patients with severe liver failure.

5.3 Preclinical safety data:

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity and genotoxicity.

Fertility and reproductive performance were not affected in studies with male and female rats given intravenous doses of tirofiban hydrochloride up to 5 mg/kg/day. These dosages are approximately 22-fold higher than the maximum recommended daily dose in humans.

However, animal studies are insufficient to draw conclusions with respect to reproductive toxicity in humans.

Tirofiban crosses the placenta in rats and rabbits.

6. PHARMACEUTICAL PARTICULARS:

6.1 List of excipients:

Acetic acid 0,5 M

Acetic acid and sodium hydroxide (for pH adjustment)

Sodium acetate trihydrate

Sodium chloride

Water for injection

6.2 Incompatibilities:

Incompatibility has been found with diazepam. Therefore, AGGREVA 0,05 mg/ml and diazepam should not be administered in the same intravenous line (see **section 4.2**).

6.3 Shelf life:

30 months.

From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user.

6.4 Special precautions for storage:

Store at or below 25 °C.

Do not freeze.

Keep container in foil over pouch to protect from light.

Keep in original packaging until required for use.

6.5 Nature and contents of container:

250 ml solution premixed is packed in a multi-layer PVC-free Polyolefin plastic infusion bag with an administration port, and an injection point for the addition of medication. Each bag is enclosed in a pre-printed foil over-pouch.

Units are packed in outer cardboard cartons with a leaflet.

6.6 Special precautions for disposal and other handling:

Do not use unless solution is clear and seal is intact.

Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as sterility may be impaired.

Any unused medicine or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER:

Teva Pharmaceuticals (Pty) Ltd.

Maxwell Office Park

Magwa Crescent West

Waterfall City

Midrand

Gauteng

2090

8. REGISTRATION NUMBER(S):

49/8.2/0091

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION:

30 November 2021

10. DATE OF REVISION OF THE TEXT: